About Triopsy
Triopsy is a Healthcare company based in Aurora (United States) founded in 2012. Medical device for precise prostate cancer diagnosis is developed. Triopsy has raised $4.14 million across 7 funding rounds from investors including Colorado Office of Economic Development and International Trade. Its chief executive, as recorded, is David G Bostwick. Triopsy offers products and services including Triopsy Biopsy System, Specimen Transport, and Renaissance LIS Software. Its focus areas include Life Sciences, Oncology, Medical Devices and Imaging. Its legal entity is Triopsy Medical, Inc. Its competitors include Exact Imaging and Clariflow; 2 of its 2 listed competitors have raised funding.
Company details
Triopsy was founded in 2012 and is headquartered in Aurora, United States. Operations focus on the medical device sector, where a system integrating biopsy and pathology technologies is utilized for identifying tumor locations, disease types, stages, and genomic profiles. This aids in diagnosis and treatment planning for prostate cancer, supporting pathways to personalized medicine.
- Headquarters Aurora, United States
- SectorsHealthcare
- Email••••••••
- Website triopsy.com
- Legal Name Triopsy Medical, Inc.
- Total Equity Funding$4.14M (USD)
in 7 rounds
- Latest Funding Round$100K (USD), Seed
Jan 2024
- Investors
Products & Services of Triopsy
Triopsy offers a comprehensive portfolio of products and services, including Triopsy Biopsy System, Specimen Transport, and Renaissance LIS Software.
Captures more tissue for accurate prostate cancer diagnosis and reduces errors.
Preserves and transports biopsy samples intact to prevent misdiagnosis.
Manages biopsy samples and generates customized pathology reports efficiently.
Funding Insights of Triopsy
Triopsy has successfully raised a total of $4.14M across 7 strategic funding rounds. The most recent funding activity was a Seed round of $100 thousand completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4.14M
- Total Rounds 7
- Last Round Seed — $100,000
- First Round $250,000
(Feb 2016)
- Investors Count 1
All 7 funding rounds of Triopsy with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2024 | $100,000 | Seed | – | – | – |
| Mar 2023 | $1.5M | Seed | – | – | – |
| May 2022 | $250,000 | Seed | – | – | – |
| Aug 2018 | $850,000 | Seed | – | – | – |
| Jul 2017 | $83,500 | Seed | – | – | – |
| Jun 2016 | $1.35M | Seed | – | – | – |
| Feb 2016 | $250,000 | Grant | – | – |
1 investors in total: 1 institutional.
Investors in Triopsy
Triopsy has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Colorado Office of Economic Development and International Trade.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Economic development and international trade are facilitated for Colorado businesses. | 2004 | advancecolorado.com | Denver, United States |
Investor details for Triopsy
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Triopsy
1 people are tracked at Triopsy (1 in leadership).
| Name | Role | Group |
|---|---|---|
David G Bostwick | CEO | Leadership |
Complete people profiles for Triopsy
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Triopsy
3 dated milestones of Triopsy across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Triopsy is founded.
- Funding First funding round of $250K.
- Funding Latest funding round, Seed, of $100K.
Competitors of Triopsy
Triopsy has 2 listed competitors in our database, 2 of them funded. They include Exact Imaging and Clariflow.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| imagistxprostate.com | 2003 | Las Vegas, United States | $4.2M | Prostate cancer imaging is enabled by micro-ultrasound technology. | ||
| clariflow.com | 2014 | New York, United States | $100,000 | Provides DIY test kits for benign prostatic hyperplasia (BPH). |
Detailed competitors of Triopsy
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Triopsy (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Triopsy
Triopsy was founded in 2012 and raised its 1st funding round 4 years after it was founded.
Triopsy is headquartered in Aurora, United States. It is registered at Aurora, Colorado, United States.
David G Bostwick is the CEO of Triopsy, as recorded in our data.
Triopsy is a funded company, having raised a total of $4.14M across 7 funding rounds to date. The company's 1st funding round was a Grant of $250K, raised on Feb 2016.
Triopsy was founded in 2012 and is headquartered in Aurora, United States. Operations focus on the medical device sector, where a system integrating biopsy and pathology technologies is utilized for identifying tumor locations, disease types, stages, and genomic profiles. This aids in diagnosis and treatment planning for prostate cancer, supporting pathways to personalized medicine.
Triopsy's top competitors include Exact Imaging and Clariflow.
Triopsy offers Triopsy Biopsy System, Specimen Transport, and Renaissance LIS Software.
Triopsy has 1 investor. Key investors include Colorado Office of Economic Development and International Trade.
Triopsy operates through Triopsy Medical, Inc..